drugset / Trial / NCT05977465
Empagliflozin in Treatment of Peripheral Diabetic Neuropathy
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of the study is to investigate the possible protective effect of empagliflozin in patients with type 2 diabetes mellitus with diabetic peripheral neuropathy and not on SGLT2 inhibitors treatment.
Timeline
- Start
- 2022-01-20
- Primary completion
- 2023-08-01
- Completion
- 2023-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 25 mg | — |